글로벌 혈장 단백질 치료제 시장 (2023-2030) : 알부민, 면역글로불린, 혈장 유래 제8인자

■ 영문 제목 : Plasma Protein Therapeutics Market Size, Share & Trends Analysis Report By Product (Albumin, Immunoglobulin, Plasma-derived Factor VIII), By Application (Hemophilia, PID, ITP), By Region, And Segment Forecasts, 2023 - 2030

Grand View Research가 발행한 조사보고서이며, 코드는 GRV23NOV281 입니다.■ 상품코드 : GRV23NOV281
■ 조사/발행회사 : Grand View Research
■ 발행일 : 2023년 9월
■ 페이지수 : 86
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (납기:3일)
■ 조사대상 지역 : 세계
■ 산업 분야 : 의약품
■ 판매가격 / 옵션 (부가세 10% 별도)
Single User (1인 열람용)USD5,950 ⇒환산₩8,032,500견적의뢰/주문/질문
Multi User (5인 열람용)USD6,950 ⇒환산₩9,382,500견적의뢰/주문/질문
Global/corporate License (기업 열람용)USD8,950 ⇒환산₩12,082,500견적의뢰/구입/질문
가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
글로벌 혈장 단백질 치료제 시장의 성장과 동향
Grand View Research사의 최신 보고서에 따르면, 세계의 혈장 단백질 치료제 시장 규모는 2023년부터 2030년까지 연평균 6. 1%의 성장률을 기록하여 2030년까지 451억 달러에 달할 것으로 예상됩니다. 이러한 성장은 출혈성 질환 및 기타 희귀 질환의 높은 유병률, 연구 개발 투자 증가, 신경학 및 기타 치료 적응증에서 혈장 유래 제품의 사용 증가에 기인합니다.

혈장 유래 단백질은 주로 만성 희귀질환 치료에 대체요법으로 사용됩니다. 이러한 약물에 의존하는 환자들은 평생 동안 정기적인 주사와 정맥주사를 필요로 합니다. 혈장 유래 제품은 250여 가지가 있지만, 주요 기업들은 일반적으로 면역글로불린(IG), 알부민, 혈액응고인자 VIII에 매출과 수익성을 의존하고 있습니다.

지난 10년간 혈장 단백질 치료제 시장은 면역글로블린이 주요 시장 점유율을 차지하며 큰 성장을 이루었습니다. 혈장 유래 제품에 대한 수요의 원동력은 질병 증가, 노인 인구의 증가, 신흥 시장에서의 의약품 접근성 향상입니다. 새로운 혈장 유래 치료법의 승인은 수요를 더욱 촉진할 것으로 예상됩니다. 중국과 브라질과 같은 개발도상국은 세계 시장 거물들에게 새로운 투자 경로를 제공합니다.

혈장 단백질 치료제 시장 보고서 하이라이트

- 면역글로불린에 대한 수요는 원발성 면역 결핍의 유행, 새로운 적응증에 대한 사용 및 투여의 용이성으로 인해 계속 증가할 것으로 예상됩니다.

- 혈액응고 제8인자 치료제 시장에서 비혈장 기반 유전자재조합 치료제가 혈장 유래 제제와 경쟁할 것으로 예상됩니다.

- 원발성 면역결핍증 부문은 2022년 26. 5%의 가장 큰 시장 점유율을 차지할 것으로 예상되며, 예측 기간 동안 6. 2%의 CAGR을 기록할 것으로 예상됩니다.

- 아시아 태평양 지역은 2022년 35. 7%로 가장 큰 시장 점유율을 차지할 것으로 예상되며, 의료비 증가, 많은 환자 수, 질병을 앓고 있는 환자와 치료를 받는 환자 비율의 개선, 저비용 의약품 생산, 진단 기술 향상 등으로 인해 예측 기간 동안 8. 6%의 가장 빠른 CAGR을 기록할 것으로 전망됩니다.
■ 보고서 개요

Chapter 1. 조사 방법 및 범위
Chapter 2. 개요
Chapter 3. 시장 변동, 동향, 범위
Chapter 4. 세계의 혈장 단백질 치료제 시장 : 제품별 예측 및 동향 분석
Chapter 5. 세계의 혈장 단백질 치료제 시장 : 용도별 예측 및 동향 분석
Chapter 6. 세계의 혈장 단백질 치료제 시장 : 지역별 예측 및 동향 분석
Chapter 7. 경쟁 현황

■ 보고서 목차

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Application
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Application outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Plasma Protein Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Plasma Protein Therapeutics market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Plasma Protein Therapeutics market: Product Estimates & Trend Analysis
4.1. Plasma Protein Therapeutics market: Key Takeaways
4.2. Plasma Protein Therapeutics market: Movement & Market Share Analysis, 2022 & 2030
4.3. Albumin
4.3.1. Albumin market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Immunoglobulin
4.4.1. Immunoglobulin market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Plasma-derived Factor VIII
4.5.1. Plasma-derived factor VIII market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Others
4.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Plasma Protein Therapeutics market: Application Estimates & Trend Analysis
5.1. Plasma Protein Therapeutics market: Key Takeaways
5.2. Plasma Protein Therapeutics market: Movement & Market Share Analysis, 2022 & 2030
5.3. Hemophilia
5.3.1. Hemophilia market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Primary Immunodeficiency Disorder (PID)
5.4.1. Primary immunodeficiency disorder (PIDD) market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Idiopathic Thrombocytopenic Purpura (ITP)
5.5.1. Idiopathic thrombocytopenic purpura (ITP) market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Others
5.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Plasma Protein Therapeutics market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Plasma Protein Therapeutics market by Region: Key Takeaways
6.3. North America
6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.6. Denmark
6.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.7. Sweden
6.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.8. Norway
6.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. CSL
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Grifols, S.A.
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Takeda
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Octapharma AG
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Biotest AG
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Kedrion S.p.A
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives

List of Tables

Table 1 List of Abbreviations
Table 2 North America plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 3 North America plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 4 North America plasma protein therapeutics market, by region, 2018 - 2030 (USD Million)
Table 5 U.S. plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 6 U.S. plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 7 Canada plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 8 Canada plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 9 Europe plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 10 Europe plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 11 Europe plasma protein therapeutics market, by region, 2018 - 2030 (USD Million)
Table 12 Germany plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 13 Germany plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 14 UK plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 15 UK plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 16 France plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 17 France plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 18 Italy plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 19 Italy plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 20 Spain plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 21 Spain plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 22 Denmark plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 23 Denmark plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 24 Sweden plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 25 Sweden plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 26 Norway plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 27 Norway plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 28 Asia Pacific plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 29 Asia Pacific plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 30 Asia Pacific plasma protein therapeutics market, by region, 2018 - 2030 (USD Million)
Table 31 Japan plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 32 Japan plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 33 China plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 34 China plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 35 India plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 36 India plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 37 Australia plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 38 Australia plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 39 Thailand plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 40 Thailand plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 41 South Korea plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 42 South Korea plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 43 Latin America plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 44 Latin America plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 45 Latin America plasma protein therapeutics market, by region, 2018 - 2030 (USD Million)
Table 46 Brazil plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 47 Brazil plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 48 Mexico plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 49 Mexico plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 50 Argentina plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 51 Argentina plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 52 Middle East and Africa plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 53 Middle East and Africa plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 54 Middle East and Africa plasma protein therapeutics market, by region, 2018 - 2030 (USD Million)
Table 55 South Africa plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 56 South Africa plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 57 Saudi Arabia plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 59 UAE plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 60 UAE plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
Table 61 Kuwait plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
Table 62 Kuwait plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
※본 조사보고서 [글로벌 혈장 단백질 치료제 시장 (2023-2030) : 알부민, 면역글로불린, 혈장 유래 제8인자] (코드 : GRV23NOV281) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [글로벌 혈장 단백질 치료제 시장 (2023-2030) : 알부민, 면역글로불린, 혈장 유래 제8인자] 에 대해서 E메일 문의는 여기를 클릭하세요.
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!